(Reuters) - The biotech firm, whose top drug satraplatin was granted priority review status by the U.S. Food and Drug Administration last month, said it was preparing for its possible launch in the United States later this year.
Peak annual sales of satraplatin, an oral drug for prostate cancer patients who fail to respond to hormone treatment, are estimated to be $500 million a year. For 2007, GPC reiterated that it expects stable revenue compared to the 22.7 million euros its garnered in 2006.
Read more at Reuters.com Market News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment